- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Audiogram.
Displaying page 1 of 2.
EudraCT Number: 2005-001487-32 | Sponsor Protocol Number: 2538 | Start Date*: 2005-12-14 |
Sponsor Name:Linköping University | ||
Full Title: Evaluation of Corticosteroids on Idiopathic Sudden Sensorineural Hearing Loss | ||
Medical condition: Idiopatic Sudden Sensorineural Hearing Loss | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002602-36 | Sponsor Protocol Number: KKSH-127 | Start Date*: 2016-06-21 |
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||
Full Title: Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT) | ||
Medical condition: Idiopathic sudden sensorineural hearing loss | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005741-17 | Sponsor Protocol Number: 76096 | Start Date*: 2021-08-25 |
Sponsor Name:Amsterdam University Medical Centers, location AMC | ||
Full Title: Hyperbaric OXygen therapy for ACute Acoustic Trauma | ||
Medical condition: Acute acoustic trauma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005215-46 | Sponsor Protocol Number: VS_Nimodipine | Start Date*: 2021-02-19 |
Sponsor Name:Department of Neurosurgery, Medical University of Vienna | ||
Full Title: Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a prospective ... | ||
Medical condition: Patients with vestibularis schwanomma undergoing microsurgical resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000132-40 | Sponsor Protocol Number: AM-111-CL-08-01 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study | |||||||||||||
Medical condition: Acute sensorineural hearing loss (ASNHL), which may be triggered by acoustic trauma, middle or inner ear surgery, i.e. known or evident insults to the inner ear. ASNHL may also result from a variet... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004182-41 | Sponsor Protocol Number: 7774 | Start Date*: 2021-11-29 |
Sponsor Name:University hospital of Montpellier | ||
Full Title: Chronic airway disease, mucus rheology and exacerbations: a randomized controlled trial of COPD patients (COPD-CARhE) | ||
Medical condition: COPD (CHRONIC OBSTUCTIVE PULMONARY DISEASE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000066-37 | Sponsor Protocol Number: NM-V-101 | Start Date*: 2013-01-16 | |||||||||||
Sponsor Name:Nordmark Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled study on efficacy, safety and tolerability of ancrod in patients with sudden sensorineural hearing loss | |||||||||||||
Medical condition: sudden sensorineural hearing loss (SSHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006243-31 | Sponsor Protocol Number: KS-OAS1 | Start Date*: 2007-05-24 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Antioxidanter vid Stapedotomi | |||||||||||||
Medical condition: Otoskleros | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005166-58 | Sponsor Protocol Number: AM-111-CL-15-01 | Start Date*: 2017-10-12 | |||||||||||
Sponsor Name:Auris Medical Inc. | |||||||||||||
Full Title: Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT) | |||||||||||||
Medical condition: Idiopathic sudden sensorineural hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001509-25 | Sponsor Protocol Number: RHMCAN0860 | Start Date*: 2012-09-25 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial A randomised, Phase II, double-blind, placebo-controlled, two arm Trial to establish whether Aspirin can reduce hearing loss/ototoxicity fo... | |||||||||||||
Medical condition: To establish whether Aspirin can reduce hearing loss/ototoxicity for patients receiving Cisplatin based chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000300-42 | Sponsor Protocol Number: 03AR0298 | Start Date*: 2013-01-18 |
Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | ||
Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome) | ||
Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-001466-42 | Sponsor Protocol Number: 17-HPNCL-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVAL | |||||||||||||
Full Title: EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATED AUDITORY BRAINSTEM RESPONSE TESTING | |||||||||||||
Medical condition: Child requiring auditory evaluation in a context of suspicion of deafness, language delay, overall developmental delay, risk factors for hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004383-19 | Sponsor Protocol Number: GORTEC_2017-01 | Start Date*: 2017-09-07 | |||||||||||
Sponsor Name:GORTEC | |||||||||||||
Full Title: A Phase III randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck | |||||||||||||
Medical condition: Squamous cell carcinoma, previously untreated Stage III, stage IVa (i.e. operable, but not operated) or IVb (non resectable) Oral cavity, oropharynx, hypopharynx or larynx | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000580-93 | Sponsor Protocol Number: SINTART2 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori | |||||||||||||
Full Title: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperab... | |||||||||||||
Medical condition: Poor prognosis inoperable sinonasal tumors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000075-33 | Sponsor Protocol Number: SINTART1 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori | |||||||||||||
Full Title: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in... | |||||||||||||
Medical condition: Poor prognosis sinonasal tumors in operable patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001144-18 | Sponsor Protocol Number: MS202359_0002 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:MERCK HEALTHCARE KGaA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement... | |||||||||||||
Medical condition: Resected squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002077-21 | Sponsor Protocol Number: AM-111-CL-13-01 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss | |||||||||||||
Medical condition: Idiopathic sudden sensorineural hearing loss | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HU (Completed) ES (Prematurely Ended) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000812-47 | Sponsor Protocol Number: SENS401-201 | Start Date*: 2018-09-24 | |||||||||||
Sponsor Name:SENSORION SA | |||||||||||||
Full Title: A two- part, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of SENS-401 in subjects with severe or profound sudden sensorineural hearing loss | |||||||||||||
Medical condition: Sudden sensorineural hearing loss (SSNHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004323-33 | Sponsor Protocol Number: AC102-201 | Start Date*: 2022-05-06 |
Sponsor Name:AudioCure Pharma GmbH | ||
Full Title: Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic ... | ||
Medical condition: Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) ISSNHL is most commonly defined as sensorineural hearing loss of 30dB or greater over at least three contiguous audiometric frequencies occurri... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) BG (Prematurely Ended) AT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004936-13 | Sponsor Protocol Number: GORTEC_2018-01 | Start Date*: 2020-05-26 | |||||||||||
Sponsor Name:GORTEC | |||||||||||||
Full Title: A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN) | |||||||||||||
Medical condition: Squamous cell carcinoma treated by primary surgery Stage III, stage IV (American Joint Committee on Cancer 7th edition) Oral cavity, oropharynx, hypopharynx or larynx | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
